@article{Stasi_Wea Chia_Kalkur_Lown_Shannon_2009, title={PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA}, volume={1}, url={https://www.mjhid.org/mjhid/article/view/2009.023}, DOI={10.4084/mjhid.2009.023}, abstractNote={<p class="MsoNormal" style="text-justify: inter-ideograph; text-align: justify; line-height: 200%; margin: 0cm 0cm 0pt;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB">Thrombocytopenia is a well recognized complication of infections, including those from hepatotropic viruses. </span><span lang="EN-US">Thrombocytopenia may actually be the only manifestation of vital hepatitis, which should therefore be considered in the differential diagnosis of primary immune thrombocytopenia (ITP). </span><span style="mso-ansi-language: EN-GB;" lang="EN-GB">The mechanisms of thrombocytopenia associated with viral hepatitis vary widely depending on the specific infectious agent and the severity of liver disease. </span><span lang="EN-US">Most of the studies have described thrombocytopenia in association with chronic hepatitis C virus (HCV) infection, the most common cause of chronic infection worldwide. Studies have shown that treatment of HCV infection often results in substantial improvement or complete recovery of the thrombocytopenia. In patients with thrombocytopenia associated with HCV-related chronic liver disease, the use of eltrombopag, a thrombopoietin receptor agonist, normalizes platelet levels thereby permitting the initiation of antiviral therapy. </span></span></span></p><span style="font-family: " lang="EN-GB"><br style="page-break-before: always; mso-special-character: line-break;" /></span>}, number={3}, journal={Mediterranean Journal of Hematology and Infectious Diseases}, author={Stasi, Roberto and Wea Chia, Lian and Kalkur, Pallavi and Lown, Robert and Shannon, Muriel S.}, year={2009}, month={Nov.}, pages={e2009023} }